ライフサイエンスコーパス: cefuroxime

1 storage, preparation, and administration of cefuroxime.

2 ghly sensitive to the beta-lactam antibiotic cefuroxime.

3 rophylaxis; all others received cefazolin or cefuroxime.

4 oxacin, 44% against TMP-SMX, and 25% against cefuroxime.

5 ere sensitive to cephalothin, cefazolin, and cefuroxime.

6 hown here to be a target for the beta-lactam cefuroxime.

7 (2 of 74, 2.7%), gram-negative bacilli with cefuroxime (1 of 209, 0.5%), and mixed species with trim

8 received or did not receive an injection of cefuroxime (5.6% vs 7.3%, respectively [P = .12]).

9 thoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuroxime (7%).

10 ingle-shot, intravenous infusion of 1.5 g of cefuroxime, a commonly used cephalosporin with a short h

11 e recent evidence suggests that intracameral cefuroxime administered at the conclusion of surgery sig

12 bility to hydrolyze cephalosporins including cefuroxime and ceftazidime has been determined by X-ray

13 o important issues are the retinal safety of cefuroxime and its use for patients with perioperative c

14 gnificantly more severe in rats treated with cefuroxime and other beta-lactams.

15 The beta-lactam ampicillin, in contrast to cefuroxime and penicillin, did not enhance encephalomyel

16 effect relationship between the injection of cefuroxime and POE.

17 d by the inhibitory beta-lactams cefotaxime, cefuroxime, and cefoxitin.

18 valuated the combination of lansoprazole and cefuroxime (another cephalosporin), which lacked evidenc

19 and safety of the prophylactic injection of cefuroxime as measured by the incidence of POE and cysto

20 tine practice, the intracameral injection of cefuroxime at the conclusion of cataract surgery is asso

21 in 101, cefazolin in 96, cefaclor in 82, and cefuroxime axetil and ceftriaxone in 22 subjects) were w

22 ficacy of oral doxycycline, amoxicillin, and cefuroxime axetil for treating Lyme disease has been est

23 nostril twice daily for 3 days and 250 mg of cefuroxime axetil twice daily for 10 days.

24 oup B participants underwent challenges with cefuroxime axetil, ceftriaxone, cefazolin, and ceftibute

25 lturing with increasing vancomycin (VAN) and cefuroxime (CEF) concentrations, we isolated an evolved

26 tant is sensitive to beta-lactams, including cefuroxime (CEF), and to fosfomycin but that resistant m

27 cillin G, ampicillin, cephalothin, cefaclor, cefuroxime, cefoperazone, and cefotaxime) were isolated,

28 itive responses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizime, and ceftaz

29 am antibiotics containing an oxyimino group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or azt

30 cted for increased resistance to cefotaxime, cefuroxime, ceftazadime, and aztreonam, i.e., the "exten

31 l subjects had negative skin test results to cefuroxime, ceftriaxone, and aztreonam and tolerated cha

32 of cross-reactivity between penicillins and cefuroxime, ceftriaxone, and aztreonam in all subjects w

33 tests with cephalexin, cefaclor, cefadroxil, cefuroxime, ceftriaxone, and aztreonam.

34 erefore these subjects could be treated with cefuroxime, ceftriaxone, and aztreonam.

35 A 30-micrograms cefuroxime disk is proposed: strains with zones > or = 2

36 A zone of inhibition around the cefuroxime disk of >/=32 mm correctly categorized 101 of

37 > or = 26 mm indicating susceptibility, but cefuroxime disks are preferred.

38 The cefuroxime doses administered to the presented patients

39 ible to penicillin, amoxicillin, cefotaxime, cefuroxime, erythromycin, chloramphenicol, vancomycin, q

40 dget impact of using Aprokam over unlicensed cefuroxime for intracameral administration.

41 arriers received vancomycin and cefazolin or cefuroxime for perioperative prophylaxis; all others rec

42 ion, quality assurance, or administration of cefuroxime formulations.

43 ylometazoline and antimicrobial therapy with cefuroxime improves clinical success rates and accelerat

44 ycin and the commercial unavailability of IC cefuroxime in many countries, moxifloxacin appears to be

45 much higher than in other reported cases of cefuroxime-induced toxicity.

46 In clinical studies, an intracameral cefuroxime injection at the end of surgery was found to

47 ma, was not increased for patients receiving cefuroxime injections (odds ratio, 0.86 [95% CI, 0.71-1.

48 Intracameral cefuroxime is recommended as prophylaxis against postope

49 xis of POE, although unlicensed intracameral cefuroxime may be administered using pre-filled syringes

50 the risk of POE was reduced with the use of cefuroxime (odds ratio, 0.61 [95% CI, 0.56-0.68]).

51 yelin basic protein T-cell line treated with cefuroxime or penicillin was more encephalitogenic in ad

52 In cases of intracameral cefuroxime overdose, hemorrhagic retinal infarction can

53 ectively [P = .001 for trend]) as the use of cefuroxime prophylactic injections increased (11.1%, 14.

54 site of pyruvate carboxylase (PycA) rescued cefuroxime resistance and resulted in a 100-fold increas

55 owever, sigma(M) still plays a major role in cefuroxime resistance even in cells lacking PBP1.

56 racterized suppressor mutations that restore cefuroxime resistance to a sigM null mutant.

57 DeltadacA mutant in rich medium and restored cefuroxime resistance.

58 Intracameral injection of cefuroxime sodium (1 mg/0.1 mL) has been reported to red

59 Intracameral injection of cefuroxime sodium at a dose of 9 mg/0.1 mL was associate

60 eyes that received intracameral injection of cefuroxime sodium, 9 mg/0.1 mL, intraoperatively.

61 he 25 920 patients who received intracameral cefuroxime, suggesting that this approach to antibiotic

62 lower for those who received an injection of cefuroxime than for those who did not (0.37% vs 0.51%, r

63 ted in T cells stimulated in the presence of cefuroxime; these genes were up-regulated in the presenc

64 n orthopedic patients, change in policy from cefuroxime to flucloxacillin (two doses of 1 g) and sing

65 ither prepared in hospital by reconstituting cefuroxime via serial dilution (prepared PFS), or commer

66 a 40% to 50% reduction in risk, intracameral cefuroxime was 100% effective in preventing endophthalmi

67 disk diffusion testing with ceftizoxime and cefuroxime was evaluated for use in predicting the susce

68 Cefuroxime was inadvertently injected at a dose higher t

69 h as meropenem, piperacillin/tazobactam, and cefuroxime, were not associated with such a risk.

70 The retinal safety of an injection of cefuroxime, which was assessed by multiadjusted odds of